Allergy Therapeutics awaits twice-delayed phase III data on its birch pollen project, while Caladrius Biosciences seeks validation of its Treg approach to type 1…
Issues with manufacturing, not exactly a new problem for Immunomedics, derail the company’s bid for glory.
US approval of Lexicon and Sanofi’s SGLT inhibitor in type 1 diabetes hangs in the balance after an adcom tie.
A look at the biggest potential drug launches this year reveals a long list of blockbusters from the likes of Alexion and Abbvie. But what impact will the shutdown have?
Fresh from a mid-stage success in depression Axsome offers an unusual way to trade its upcoming phase III result.
Venture capital firms invested a record $16.8bn in private drug developers globally in 2018, but signs of a cooling are clear.
Celgene had many fingers in many pies – so what will happen now to its smaller collaborators?
Despite encouraging interim pivotal data, Carmat’s artificial heart seems as far from market as ever.
Was 2018 as good as it gets for drug approvals, or is the pipeline so stellar that even a US government shutdown cannot stop biopharma?
The immensely complex and long-running intertwined litigation between the two medtechs has been brought to an end.
The takeover of Celgene has disrupted pharma’s conventional wisdom on which companies should merge and when. This is how things now stand.
The fastest share price growth in medtech is always recorded by small-caps, but Tandem reached a new extreme last year.
Pfizer is said to be interested in Amarin, but the Danish group’s need for a growth injection is greater.
Some medtech stocks did decline in 2018, but many more increased in value.
Jazz wants to expand its sleep portfolio, while Macrogenics hopes trial data will support its first new drug application.
The buoyant biopharma IPO scene set several new records in 2018, a notable achievement given the stock market turmoil of the fourth quarter.
Investors swerve traditional medical devices in favour of artificial intelligence-enabled diagnostics.
Day three of the biotech dog and pony show saw one pharma company that unequivocally wants and needs to buy.
After Monday’s celebrations the sector gets down to discussing the difficult business of actually selling and making money from drugs.
Takeda gave biopharma’s M&A bill a big boost in 2018 but to see just how slow the year was, take a look at deal volumes.